115 results about "Blood disease" patented technology

The invention belongs to the technical field of medical treatment, and discloses a blood product virus inactivation system based on a synergistic effect of nano-catalysis photochemical inactivation and low-temperature plasma, the system comprises: a nano-photocatalysis inactivation module adopting titanium dioxide TiO2 and graphite phase carbon nitride g-C3N4 nano-materials as photocatalysts; the low-temperature plasma inactivation module adopts a low-temperature plasma generator to generate plasma cloud above the blood product and release active particles; the dynamic fluid stirring module is used for enabling the blood product to uniformly receive photocatalysis and plasma inactivation effects through a microfluid mixing technology so as to ensure the uniformity of virus inactivation; the sensing monitoring and intelligent feedback module is used for monitoring the residual quantity of viral nucleic acid and the activity of protein in the blood in real time by adopting a spectrum sensor and a biochemical sensor. The method can be widely applied to the fields of clinical blood transfusion, blood product manufacturing, blood disease treatment and the like, promotes the progress of a blood safety guarantee technology, reduces the virus infection risk and improves the patient safety.

The invention belongs to the technical field of medical detection, and discloses a blood disease high-throughput detection method based on a micro-fluidic chip and SERS (Surface Enhanced Raman Scattering) detection, which comprises the following steps: introducing a blood sample into the micro-fluidic chip with a micro-fluidic channel; the method comprises the following steps: performing SERS (Surface Enhanced Raman Scattering) detection on a blood sample through a nano-structure surface preset in a micro-fluidic channel; according to the present invention, with the microfluidic chip and the SERS technology, the high-throughput detection of the blood sample is achieved, the SERS spectrum data is collected and analyzed, the disease marker in the blood is identified, and the high-throughput detection of the blood sample is achieved through the combination of the microfluidic chip and the SERS technology. A plurality of micro-channels on the micro-fluidic chip can process a plurality of samples in parallel, the detection efficiency is remarkably improved, and the strength of Raman scattering signals can be remarkably improved by utilizing the surface enhancement effect of the SERS technology, so that high-sensitivity detection of blood disease markers is realized, and the detection cost is reduced. Accurate control and efficient separation of trace samples are achieved through the micro-fluidic chip, complex pretreatment steps are not needed, and the operation process is simplified.

The invention relates to the technical field of medical information systems, in particular to a blood smear abnormal cell intelligent recognition system and method based on deep learning. The multi-stage convolutional neural network module is in data connection with the image acquisition module, and the abnormal cell bank module is in data connection with the multi-stage convolutional neural network module; the knowledge graph module is in data connection with the abnormal cell bank module, and the blood index calculation module is in data connection with the multistage convolutional neural network module and the abnormal cell bank module and is used for calculating various blood indexes; generating a graphical display result of the blood indexes; the result output module is in data connection with the knowledge graph module and the blood index calculation module; according to the blood disease diagnosis method and system, the whole process from image acquisition to diagnosis report generation can be automatically completed, detailed analysis results and diagnosis suggestions can be provided for doctors, and the efficiency and accuracy of blood disease diagnosis are greatly improved.

A monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. A nucleic acid encoding the antibody or antigen-binding fragment thereof, an expression vector, a method for preparing the antibody, and use of the antibody in treatment of diseases or disorders associated with the human T cell receptor family. The generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The invention provides a semantic search method and system for blood disease medical record big data, and relates to the technical field of medical information processing.The method comprises the steps that firstly, a blood disease medical record semantic association network is constructed, medical record text units serve as nodes, semantic association relationships serve as edges, and related information of the nodes and the edges is marked; analyzing a user search intention to generate a search semantic vector, calling semantic association network information to perform dynamic semantic matching to obtain a matched medical record text unit set, generating a hierarchical search result according to a matching result, dividing and sorting according to a matching dimension, and generating semantic association interpretation; and finally, based on the access behavior feedback of the user to the hierarchical search result, optimizing the semantic association network, recording user clicking, staying and secondary search triggering conditions, and adjusting the node association priority, edge association strength and weight to improve the accuracy and practicability of blood disease medical record search.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention relates to the technical field of medical informatization, and particularly discloses a blood disease intelligent diagnosis and treatment data processing system which adopts an image processing technology based on deep learning to perform cell detection on a bone marrow morphological image of a patient object so as to focus on a cell target in the image. The method comprises the following steps: acquiring a cell target, performing multi-level feature extraction on the cell target to capture superficial detail features and trunk features of the cell, and performing significant sparse interactive coding on the superficial detail features and the trunk features to obtain cell feature representation with higher distinction degree, thereby realizing intelligent identification of abnormal cells. Through the mode, the cell characteristics in the blood sample can be automatically identified and analyzed, and rapid detection and diagnosis of abnormal cells are realized, so that a doctor can be assisted to carry out faster and more accurate blood disease diagnosis, and the workload of the doctor is relieved.

The invention provides a cyclic compound with a structure as shown in a formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule of the cyclic compound, and a pharmaceutical composition and application of the cyclic compound or the pharmaceutically acceptable salt or the stereoisomer or the prodrug molecule of the cyclic compound. The compound can be used as a protein kinase inhibitor, has very strong inhibitory activity on FLT3 mutant kinase, has very strong proliferation inhibitory activity on Ba / F3-FLT3-ITD and stable strain cells containing drug-resistant point mutation, can inhibit proliferation, migration and invasion of various tumor cells, and especially can overcome the drug resistance of existing clinical drugs. The cyclic compound provided by the invention can be used for preparing medicines for preventing or treating FLT3 tyrosine kinase mediated diseases (such as hematological malignancies), and can be used for treating various hematological malignancies of human beings and other mammals. # imgabs0 #

Provided herein are antibodies, compositions, and methods of use thereof. The disclosed antibodies bind to von Willebrand factor in blood plasma of a subject. Such antibodies are useful for methods of treatment, such methods of treating one or more blood disorders characterized by excessive bleeding.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention discloses a KMT2A fusion gene detection primer probe group, a kit and a detection method, the primer probe group is specifically designed based on KMT2A gene fusion and 13 common partner genes MLLT3, AFF1, MLLT10, MLLT1, MLLT4, ELL, EPS15, SEPT6, MLLT11, MLLT6, SEPT9, AFF3 and CBL fusion sites, the mutual interference is small, the primer probe group can be used for targeted amplification of a fusion gene specific region in a single-tube mixed solution, the detection sensitivity is high, the detection time is short, the detection time is short, and the detection efficiency is high. According to the present invention, the rapid detection of any one fusion gene type in 67 types can be achieved, and compared with the high-throughput sequencing, the sensitivity is high, the detection rate is high, the single sample detection cost is low, the method is suitable for the clinical auxiliary diagnosis of the large batch of samples, and the guidance is provided for the diagnosis, the treatment and the prognosis of the blood disease patients.

The invention belongs to the technical field of traditional Chinese medicine acupuncture instruments, and discloses a protective jacket of a disposable acupuncture needle and a hand pressing needle inserting device. The protective jacket comprises a flexible film sleeve and a sleeve which are sleeved on the needle body, the top end of the flexible film sleeve is fixed on the needle root or the needle handle of the acupuncture needle, and the bottom end of the flexible film sleeve is fixed at the top end of the sleeve. The middle of the sleeve is in a flat shape with the oval cross section and is in interference fit with the needle body to clamp and fix the needle body, and the two ends of the sleeve are in clearance fit with the needle body. The sleeve of the protective jacket can cover the needle tip, the flat and flat section can clamp and fix the needle body, the risk that the needle tip accidentally pierces out to cause needle injury in the transportation or taking process can be reduced, and the needle tip can be collected into the sleeve and fixed after the needle is withdrawn; the risk that a used acupuncture needle punctures a needle applicator or other people and the risk of blood disease infection can be reduced, the hand pressing needle inserting device is used for clamping the protective jacket to assist in needle inserting, and the flat and flat section can be conveniently extruded to relieve clamping of the flat and flat section to a needle body.

The invention discloses an application of a natural product WithangatinA in preparation of erythroleukemia induced differentiation treatment drugs, the natural product WithangatinA promotes HEL and K562 cells to be transformed from malignant proliferative cells to normal megakaryocytes by inducing the cell particle size to become larger and significantly increasing multinuclear megakaryocytes and promoting expression of surface labeled molecules differentiated from megakaryocytes at the same time, and the erythroleukemia induced differentiation treatment drugs are obtained. The effect of resisting erythroleukemia is achieved. After the natural product Withangulin A is adopted for treatment, the size and the weight of the spleen of a leukemia mouse can be remarkably reduced, the hematocrit and the platelet number of the mouse are remarkably increased, in addition, treatment of the natural product Withangulin A has no obvious influence on the weight of the mouse, and the safety is high. In-vivo research shows that the medicine can induce megakaryocyte differentiation of erythroleukemia in a mouse body, the effect of resisting erythroleukemia is achieved, and a research basis is provided for development of differentiation treatment medicines of erythroleukemia.

The present invention relates to nicotinamide mononucleotide derivatives of Formula (I)for use in the treatment and / or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and / or prevention of a red blood cell disorder, especially sickle cell disease.

Provided herein is a method of treating a blood disorder such as sickle cell disease or a β-hemoglobinopathy with an Embryonic Ectoderm Development (EED) inhibitor as described herein.

The invention discloses a blood detection system and method based on an RRAM, relates to the technical field of integrated circuit design, and aims to solve the problem of how to improve the detection efficiency and accuracy of blood detection. The system comprises a computing chip, an RRAM chip, a power supply module and a sensor module, the calculation chip is connected with the RRAM chip, the RRAM chip is connected with the sensor module, and the power supply module is connected with the calculation chip and the RRAM chip; the sensor module is used for detecting substances in blood and converting detection result data into a plurality of first voltage data; the RRAM chip is used for carrying out data preprocessing on the received multiple pieces of first voltage data to obtain second current data; the calculation chip is used for performing function calculation on the second current data according to a preset function calculation model on the basis of the second current data to obtain a classification result of the blood; therefore, the blood is detected by using the integrated circuit, and the efficiency and accuracy of screening diseases in the blood are improved.

The invention provides a blood disease AI diagnosis assisting system. The system comprises a data acquisition module used for acquiring multi-modal data; the feature extraction module is used for performing feature extraction on the multi-modal data based on a preset fusion feature extraction strategy to obtain fusion features; the scheme generation module is used for generating a reference scheme which corresponds to the fusion features and is used for blood disease auxiliary diagnosis through a preset diagnosis-assisting scheme generation strategy according to the fusion features; the score acquisition module is used for acquiring a score matrix; the evaluation module is used for determining a comprehensive score of the reference scheme as an evaluation result according to the score matrix; and the feedback adjustment module is used for adjusting hyper-parameters in a preset fusion feature extraction strategy and / or a preset diagnosis assisting scheme generation strategy according to the evaluation result. Therefore, the problem that the finally output reference pathology recognition result is inaccurate due to the fact that the data mode of pathology recognition is single in the traditional hematological disease assisted diagnosis and assisted teaching process can be solved.

The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder:wherein RA, RB, RC and RD, X, Y1, Y2, Y3, Z1, Z2 and m are as defined herein.

The invention relates to the technical field of medical equipment, in particular to a portable diagnosis and treatment instrument for blood disease treatment, which comprises a box body and moving wheels, an opening is formed in the upper end of the box body, locking openings are formed in two sides of the top of the box body, and the moving wheels are mounted on the box body; the partition plate is fixedly mounted in the middle of the box body; the access mechanism is installed on the box body, the control end of the access mechanism is arranged outside the box body, and the power output end of the access mechanism is fixedly connected with diagnosis and treatment equipment; the outward pushing mechanisms are fixedly installed on the two sides of the partition plate, extending mechanisms penetrate through the outward pushing mechanisms on the two sides, and one ends of the extending mechanisms are connected with the diagnosis and treatment equipment; the box cover is matched with the opening of the box body, rotary knobs are rotationally installed on the two sides of the box cover, and clamping plates are fixedly arranged on the rotary knobs; and the handle is fixedly mounted on the box cover. The portable diagnosis and treatment instrument for blood disease treatment provided by the invention not only can diagnose and treat blood diseases, but also has better portability, meanwhile, diagnosis and treatment equipment can be quickly taken out or put into the box body, the operation is simple, and the practicability is high.

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.

The invention relates to the technical field of analysis of chemical components of Xinnaoxin, and particularly discloses a method for detecting chemical components of Xinnaoxin based on UPLC-Q-TOF-MS. The method comprises the following steps: preparing a test solution through alcohol solvent extraction; then the test solution is determined by adopting a UPLC-Q-TOF-MS method, various chemical components of Xinnaoxin can be effectively separated out under specific chromatographic conditions, and the detection sensitivity and accuracy can be improved under specific mass spectrum conditions. 92 kinds of compounds in a heart and brain aoxin sample are finally identified, and the active ingredients of different kinds and different sources have a treatment effect on many heart blood diseases in a synergistic or complementary mode. By adopting the UPLC-Q-TOF-MS method, the chemical components of the Xinnaoxin sample can be rapidly and accurately detected, and reference is provided for promoting secondary development of preparations based on Xinnaoxin and deeper research and development of Xinnaoxin medicines.

Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematological disease or disorder such as multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The effective amount of the anti-CD33 targeting agent may be an amount sufficient to induce myeloconditioning or an amount to induce myeloablation. The methods may further include transplanting allogeneic stem cells to the patient after administration of the anti-CD33 targeting agent.

The present invention discloses a multi-model fusion classification method based on blood diseases, comprising the following steps: obtaining a data set; dividing the data set into k parts based on a k-fold cross-validation method to obtain a test set and a training set, where k is any constant greater than 1; selecting a plurality of machine learning binary classifier models for data set training; fusing a plurality of machine learning binary classifier models by linear addition to obtain a fused multi-classifier model; using the machine learning multi-classifier model to train a multi-label data set to obtain a model accuracy rate; using the fused multi-classifier model to train a multi-label data set to obtain an accuracy rate of the fused multi-classifier model, and comparing it with the above accuracy rate. The present invention adopts the above-mentioned multi-model fusion classification method based on blood diseases, which can quickly classify blood diseases to help doctors quickly diagnose, reduce doctors' workload, and improve their work efficiency.

The present invention provides a pulse-type blood-drawing device for patients with blood diseases, belonging to the technical field of medical devices. The device comprises a support base, a limiting groove is provided on the top outer wall of the support base, a heating pad is installed on the inner wall of the limiting groove, a first C-shaped buckle is fixedly connected to the top inner wall of the support base, sliding grooves are provided on the outer walls of both sides of the support base, a plurality of latching teeth are fixedly connected to the inner walls of the sliding grooves, and connecting columns are symmetrically fixedly connected to the outer walls of both sides of the support base; a pulse-drawing component is used to promote blood collection after the venous blood filling is apparent. The pulse-drawing component can be set up to inflate a rubber airbag by stepping on a foot pump, thereby compressing the patient's arm vein, making the vein more filled with blood, and facilitating medical personnel to find a suitable vein for puncture. Such a setting can avoid medical personnel from feeling fatigued due to frequent bending or stretching of the arms, as well as the restriction of heavy clothing.

The present invention belongs to the technical field of analytical chemistry, and specifically relates to a quality detection method for a traditional Chinese medicine composition for treating gynecological blood diseases. The quality detection method includes a thin layer chromatography qualitative detection method and a content detection method. The thin layer chromatography qualitative detection method uses isochlorogenic acid A and isochlorogenic acid B as reference substances, and is used in conjunction with Yunnan Guiyina Balsamifera reference medicinal materials to identify the sample. The method is used to analyze the sample, and the obtained thin layer chromatography separation effect is good, the spots are round and clear, and the development rate is fast. The result is easy to judge, and the sample can be quickly and accurately identified. The content detection method of the present invention has a relatively appropriate peak time and good separation. After methodological investigation, it was found that the specificity, stability, repeatability, intermediate precision, accuracy, etc. of the two methods all meet the requirements. The quality detection method provided by the present invention can be used to comprehensively control the quality of the traditional Chinese medicine composition, and further ensure the stability and controllability of the efficacy of the traditional Chinese medicine composition.

The application discloses a bone marrow morphology acute event identification early warning system and relates to the technical field of intelligent medical treatment, and the technical solution points are as follows: acquiring bone marrow cell image data, pre-processing, obtaining pre-processed image data; inputting the pre-processed image data into a trained AI model, and outputting a classification prediction result. The application can more accurately identify and classify bone marrow cells by applying a visual Transformer and a visual Mamba model, can identify different cell development stages, and can diagnose various blood diseases through an AI model standardized analysis process, reduce professional barriers in the field of bone marrow morphology, reduce absolute dependence on expert experience, and enable areas with insufficient medical conditions to also obtain high-quality preliminary diagnosis.

The invention relates to the technical field of analysis of chemical components of Xinnaoxin, and particularly discloses a method for detecting all chemical components of Xinnaoxin based on UPLC-Q-TOF-MS. The method comprises the following steps: preparing a test solution through alcohol solvent extraction; then, the test sample solution is determined by adopting a UPLC-Q-TOF-MS method, various chemical components of Xinnaoxin can be effectively separated out under specific chromatographic conditions, and the detection sensitivity and accuracy can be improved under specific mass spectrum conditions. According to the invention, 102 compounds in a heart and brain aoxin sample are finally identified, and the active ingredients of different types and sources have a treatment effect on a plurality of heart blood diseases in a synergistic or complementary manner. By adopting the UPLC-Q-TOF-MS method, the chemical components of the Xinnaoxin sample can be rapidly and accurately detected, and reference is provided for promoting secondary development of preparations based on Xinnaoxin and deeper research and development of Xinnaoxin medicines.

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The invention discloses a blood disease marrow fluid sample collection device, and belongs to the technical field of medical instruments, the device comprises a collection main body, a first piston assembly, a second piston assembly and a filter assembly, the collection main body is internally provided with a first chamber; the first piston assembly is arranged in the first cavity, the second cavity is formed in a piston rod body of the first piston assembly, the second piston assembly is arranged in the second cavity, and the second cavity and the first cavity are connected through a second cavity communicating channel; the filtering assembly is arranged at the front end of the communicating channel of the second cavity, after the first piston assembly is driven to extract marrow fluid into the first cavity, the collecting body is removed from the puncture needle, and the second piston assembly is driven to suck the marrow fluid in the first cavity into the second cavity; the bone marrow particle tissue in the bone marrow fluid in the first cavity is collected through the filter screen, separated collection of the bone marrow fluid and the bone marrow particles is completed, the complete structure of the bone marrow particles can be guaranteed, and the collection efficiency is higher.